These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 29862538)
1. Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy. Lou Y; Lu Y; Zhu Z; Ma Y; Suo S; Wang Y; Chen D; Tong H; Qian W; Meng H; Mai W; Yu W; Xu W; Wang L; Mao L; Pei R; Jin J Hematol Oncol; 2018 Jun; ():. PubMed ID: 29862538 [TBL] [Abstract][Full Text] [Related]
2. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN; Chen JP; Liu JP; Xia Y Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733 [TBL] [Abstract][Full Text] [Related]
3. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA. Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588 [TBL] [Abstract][Full Text] [Related]
4. [The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients]. Lu Y; Li F; Mu Q; Meng H; Qian W; Tong H; Mai W; Pei R; Yu M; Zhao X; Jin J Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):372-7. PubMed ID: 26031521 [TBL] [Abstract][Full Text] [Related]
5. Therapy-related myeloid neoplasms following curative treatment of acute promyelocytic leukemia: incidence, correlation with therapeutic regimen, and future directions. Menon A; Sukhanova M; Gao J; Wolniak K; Fu L; Chen YH; Chen QC; Tariq H J Hematop; 2024 Dec; 17(4):201-208. PubMed ID: 39254828 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience. Autore F; Chiusolo P; Sorà F; Giammarco S; Laurenti L; Innocenti I; Metafuni E; Piccirillo N; Pagano L; Sica S Front Oncol; 2021; 11():614721. PubMed ID: 34336637 [TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734 [TBL] [Abstract][Full Text] [Related]
8. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. Gill H; Raghupathy R; Lee CYY; Yung Y; Chu HT; Ni MY; Xiao X; Flores FP; Yim R; Lee P; Chin L; Li VWK; Au L; Au WY; Ma ESK; Mohan D; Kumana CR; Kwong YL BMC Cancer; 2023 Feb; 23(1):141. PubMed ID: 36765318 [TBL] [Abstract][Full Text] [Related]
9. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). Wang HY; Gong S; Li GH; Yao YZ; Zheng YS; Lu XH; Wei SH; Qin WW; Liu HB; Wang MC; Xi JY; Chen LM; Zhang M; Zhang XX; Zhang HY; Zhang CS; Wald DN; Zhu HH; Liu L; He PC Blood Cancer J; 2022 Nov; 12(11):158. PubMed ID: 36404343 [TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Kayser S; Krzykalla J; Elliott MA; Norsworthy K; Gonzales P; Hills RK; Baer MR; Ráčil Z; Mayer J; Novak J; Žák P; Szotkowski T; Grimwade D; Russell NH; Walter RB; Estey EH; Westermann J; Görner M; Benner A; Krämer A; Smith BD; Burnett AK; Thiede C; Röllig C; Ho AD; Ehninger G; Schlenk RF; Tallman MS; Levis MJ; Platzbecker U Leukemia; 2017 Nov; 31(11):2347-2354. PubMed ID: 28322237 [TBL] [Abstract][Full Text] [Related]
11. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939 [TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214 [TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia. Park YH; Kim DY; Mun YC; Cho EK; Lee JH; Jo DY; Kim I; Yoon SS; Park SY; Kim B; Bang SM; Kim H; Min YJ; Park JH; Seo JJ; Moon HN; Lee MH; Kim CS; Lee WS; Chong SY; Oh D; Zang DY; Lee KH; Hyun MS; Kim HS; Kim SH; Kwon H; Kim HJ; Park KT; Bae SH; Ryoo HM; Choi JH; Ahn MJ; Yoon HJ; Nam SH; Kim BS; Seong CM Korean J Intern Med; 2022 Jul; 37(4):841-850. PubMed ID: 35811370 [TBL] [Abstract][Full Text] [Related]
15. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia. Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675 [TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). Chen L; Zhu HM; Li Y; Liu QF; Hu Y; Zhou JF; Jin J; Hu JD; Liu T; Wu DP; Chen JP; Lai YR; Wang JX; Li J; Li JY; Du X; Wang X; Yang MZ; Yan JS; Ouyang GF; Liu L; Hou M; Huang XJ; Yan XJ; Xu D; Li WM; Li DJ; Lou YJ; Wu ZJ; Niu T; Wang Y; Li XY; You JH; Zhao HJ; Chen Y; Shen Y; Chen QS; Chen Y; Li J; Wang BS; Zhao WL; Mi JQ; Wang KK; Hu J; Chen Z; Chen SJ; Li JM Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33495363 [TBL] [Abstract][Full Text] [Related]
17. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide. Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245 [TBL] [Abstract][Full Text] [Related]
18. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis. Ma Y; Liu L; Jin J; Lou Y PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027 [TBL] [Abstract][Full Text] [Related]
19. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912 [TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]